Utility of PET/CT in patients with stage I-III melanoma

Clin Transl Oncol. 2020 Aug;22(8):1414-1417. doi: 10.1007/s12094-019-02252-2. Epub 2019 Dec 23.

Abstract

Purpose: To study the utility of positron emission tomography with computerized tomography (PET/CT) in patients with a stage I-III melanoma.

Patients and methods: PET/CT findings from all patients with a stage I-III melanoma attended at our hospital from September 2011 to November 2015 were reviewed.

Results: Data from 83 patients with a stage I-III melanoma, 39 patients with a positive sentinel lymph node biopsy (SLNB) and 35 patients with locoregional recurrences were analyzed. Sensitivity of PET/CT in clinical stage I-III patients was 5%, with a 14% of false positives. In patients with a positive SLNB, PET/CT previous to complete lymph node dissection had a 23% of false negatives. In patients with clinical locoregional recurrences, PET/CT findings revealed asymptomatic visceral distant metastasis in 25.7%.

Conclusions: PET/CT has a significant rate of false positive and negative results in patients with a stage I-III melanoma. Utility in patients with nodal locoregional recurrences seems higher than in patients with skin metastases.

Keywords: Complete lymph node dissection; Diagnosis; Melanoma; PET/CT; Sentinel lymph node biopsy; Skin metastases; Staging.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • False Negative Reactions
  • False Positive Reactions
  • Female
  • Humans
  • Lymph Node Excision
  • Male
  • Melanoma / diagnostic imaging*
  • Melanoma / mortality
  • Melanoma / pathology
  • Melanoma / surgery
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / surgery
  • Positron Emission Tomography Computed Tomography*
  • Retrospective Studies
  • Sensitivity and Specificity
  • Sentinel Lymph Node Biopsy*
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology
  • Skin Neoplasms / surgery